- Home
- PCN vs JANX Comparison
PCN vs JANX Comparison
Compare PCN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCN | JANX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.1M | 790.3M |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PCN | JANX |
|---|---|---|
| Price | $11.83 | $14.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 289.9K | ★ 876.7K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.40 | $12.12 |
| 52 Week High | $13.49 | $35.34 |
Technical Indicators
Market Signals| Indicator | PCN | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 35.70 | 47.13 |
| Support Level | $11.40 | $13.88 |
| Resistance Level | $12.12 | $14.44 |
| Average True Range (ATR) | 0.07 | 0.54 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 1.68 | 29.59 |
Price Performance
Historical ComparisonAbout PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.